<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>/reperfusion, <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation leads to the formation of toxic <z:chebi fb="5" ids="17478">aldehydes</z:chebi> that contribute to ischemic dysfunction </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001427'>Mitochondrial</z:hpo> <z:chebi fb="1" ids="17478">aldehyde</z:chebi> dehydrogenase type 2 (ALDH2) alleviates ischemic heart damage and reperfusion <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> via <z:chebi fb="1" ids="17478">aldehyde</z:chebi> detoxification </plain></SENT>
<SENT sid="2" pm="."><plain>Because excessive <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> release in the heart is a pivotal arrhythmogenic mechanism, we hypothesized that neuronal ALDH2 activation might diminish ischemic <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> release </plain></SENT>
<SENT sid="3" pm="."><plain>Incubation of cardiac sympathetic nerve endings with <z:chebi fb="0" ids="15343,43923">acetaldehyde</z:chebi>, at concentrations achieved in <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>, caused a concentration-dependent increase in <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> release </plain></SENT>
<SENT sid="4" pm="."><plain>A major increase in <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> release also occurred when sympathetic nerve endings were incubated in hypoxic conditions </plain></SENT>
<SENT sid="5" pm="."><plain>ALDH2 activation substantially reduced <z:chebi fb="0" ids="15343,43923">acetaldehyde</z:chebi>- and <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> release, an action prevented by inhibition of ALDH2 or protein kinase Cε (PKCε) </plain></SENT>
<SENT sid="6" pm="."><plain>Selective activation of G(i/o)-coupled <z:chebi fb="3" ids="16335">adenosine</z:chebi> A(1), A(3), or <z:chebi fb="11" ids="18295">histamine</z:chebi> H(3) receptors markedly inhibited both <z:chebi fb="0" ids="15343,43923">acetaldehyde</z:chebi>- and <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> release </plain></SENT>
<SENT sid="7" pm="."><plain>These effects were also abolished by PKCε and/or ALDH2 inhibition </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, A(1)-, A(3)-, or H(3)-receptor activation increased ALDH2 activity in a sympathetic neuron model (differentiated PC12 cells stably transfected with H(3) receptors) </plain></SENT>
<SENT sid="9" pm="."><plain>This action was prevented by the inhibition of PKCε and ALDH2 </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings suggest the existence in sympathetic neurons of a protective pathway initiated by A(1)-, A(3)-, and H(3)-receptor activation by <z:chebi fb="3" ids="16335">adenosine</z:chebi> and <z:chebi fb="11" ids="18295">histamine</z:chebi> released in close proximity of these terminals </plain></SENT>
<SENT sid="11" pm="."><plain>This pathway comprises the sequential activation of PKCε and ALDH2, culminating in <z:chebi fb="1" ids="17478">aldehyde</z:chebi> detoxification and inhibition of hypoxic <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> release </plain></SENT>
<SENT sid="12" pm="."><plain>Thus, pharmacological activation of PKCε and ALDH2 in cardiac sympathetic nerves may have significant protective effects by alleviating <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi>-induced life-threatening <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> that characterize <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>/reperfusion </plain></SENT>
</text></document>